Drug penetration across the blood-brain barrier: An overview

Therapeutic Delivery

Volumn 1, Issue 4, 2010, Pages 535-562

  Mangas Sanjuan, V ^a   Gonzalez Alvarez M ^a   Gonzalez Alvarez, I ^a   Bermejo, M ^a  

^a MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE; CENTRAL NERVOUS SYSTEM AGENTS; DYSTROGLYCAN; ESTERASE; GLYCOPROTEIN P; HEXOSE; INSULIN; INTEGRIN; NERVE GROWTH FACTOR; OXIDOREDUCTASE; POLY(ISOBUTYL 2 CYANOACRYLATE); PRODRUG; VIRUS VECTOR;

ALZHEIMER DISEASE; ARTIFICIAL MEMBRANE; ASTROCYTE; AUTORADIOGRAPHY; BASEMENT MEMBRANE; BLOOD BRAIN BARRIER; BRAIN HOMOGENATE; BRAIN SLICE; CAPILLARY ENDOTHELIUM; CELL IMMORTALIZATION; CHROMATOGRAPHY; COMBINATORIAL CHEMISTRY; COMPUTER MODEL; DRUG ADMINISTRATION ROUTE; DRUG METABOLISM; DRUG PENETRATION; ENDOTHELIUM CELL; EQUILIBRIUM DIALYSIS; EXTRACELLULAR MATRIX; HOLLOW FIBER; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIPOPHILICITY; MACROMOLECULE; MEMBRANE TRANSPORT; MICRODIALYSIS; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATION REDUCTION STATE; PERICYTE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; TRANSCYTOSIS;

EID: 79954519753     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.10.37     Document Type: Review

References (267)

1. Pavan B, Dalpiaz A, Ciliberti N, Biondi C, Manfredini S, Vertuani S. Progress in drug delivery to the central nervous system by the prodrug approach. Molecules. 13, 1035-1065 (2008).
2. Abbott NJ. Inflammatory mediators and modulation of blood-brain barrier permeability. Cell Mol. Neurobiol. 20, 131-147 (2000). (Pubitemid 30091452)
3. Gaillard PJ, de Boer AB, Breimer DD. Pharmacological investigations on lipopolysaccharide-induced permeability changes in the blood-brain barrier in vitro. Microvasc. Res. 65, 24-31 (2003). (Pubitemid 36263287)
4. Lo EH, Singhal AB, Torchilin VP, Abbott NJ. Drug delivery to damaged brain. Brain Res. Brain Res. Rev. 38, 140-148 (2001). (Pubitemid 34066499)
5. Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2, 3-14 (2005). (Pubitemid 40128022)
6. Friden M, Winiwarter S, Jerndal G et al. Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids. J. Med. Chem. 52, 6233-6243 (2009).
7. Hammarlund-Udenaes M, Bredberg U, Friden M. Methodologies to assess brain drug delivery in lead optimization. Curr. Top. Med. Chem. 9, 148-162 (2009).
8. Hammarlund-Udenaes M, Friden M, Syvanen S, Gupta A. On the rate and extent of drug delivery to the brain. Pharm. Res. 25, 1737-1750 (2008).
9. Summerfield SG, Read K, Begley DJ et al. Central nervous system drug disposition: the relationship between in situ brain permeability and brain free fraction. J. Pharmacol. Exp. Ther. 322, 205-213 (2007). (Pubitemid 46956363)
10. Nicolazzo JA, Charman SA, Charman WN. Methods to assess drug permeability across the blood-brain barrier. J. Pharm. Pharmacol. 58, 281-293 (2006). (Pubitemid 43344570)
11. Engelhardt B, Sorokin L. The blood-brain and the blood-cerebrospinal fluid barriers: function and dysfunction. Semin. Immunopathol. 31, 497-511 (2009).
12. Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol. Rev. 57, 173-185 (2005). (Pubitemid 41043883)
13. Wolburg H, Lippoldt A. Tight junctions of the blood-brain barrier: development, composition and regulation. Vascul. Pharmacol. 38, 323-337 (2002). (Pubitemid 36398254)
14. Bauer HC, Bauer H. Neural induction of the blood-brain barrier: still an enigma. Cell. Mol. Neurobiol. 20, 13-28 (2000). (Pubitemid 30090913)
15. Garberg P, Ball M, Borg N et al. In vitro models for the blood-brain barrier. Toxicol. In Vitro 19, 299-334 (2005). (Pubitemid 40248750)
16. Betsholtz C, Lindblom P, Bjarnegard M, Enge M, Gerhardt H, Lindahl P. Role of platelet-derived growth factor in mesangium development and vasculopathies: lessons from platelet-derived growth factor and platelet-derived growth factor receptor mutations in mice. Curr. Opin. Nephrol. Hypertens. 13, 45-52 (2004). (Pubitemid 39069898)
17. Nakagawa S, Deli MA, Nakao S et al. Pericytes from brain microvessels strengthen the barrier integrity in primary cultures of rat brain endothelial cells. Cell. Mol. Neurobiol. 27, 687-694 (2007). (Pubitemid 47476613)
18. Sixt M, Engelhardt B, Pausch F, Hallmann R, Wendler O, Sorokin LM. Endothelial cell laminin isoforms, laminins 8 and 10, play decisive roles in T cell recruitment across the blood-brain barrier in experimental autoimmune encephalomyelitis. J. Cell Biol. 153, 933-946 (2001).
19. del Zoppo GJ, Milner R. Integrin-matrix interactions in the cerebral microvasculature. Arterioscler. Thromb. Vasc. Biol. 26, 1966-1975 (2006). (Pubitemid 44253776)
20. Del Zoppo GJ, Milner R, Mabuchi T, Hung S, Wang X, Koziol JA. Vascular matrix adhesion and the blood-brain barrier. Biochem. Soc. Trans. 34, 1261-1266 (2006). (Pubitemid 46769034)
21. Agrawal S, Anderson P, Durbeej M et al. Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis. J. Exp. Med. 203, 1007-1019 (2006).
22. Wu C, Ivars F, Anderson P et al. Endothelial basement membrane laminin a5 selectively inhibits T lymphocyte extravasation into the brain. Nat. Med. 15, 519-527 (2009).
23. Durbeej M, Henry MD, Ferletta M, Campbell KP, Ekblom P. Distribution of dystroglycan in normal adult mouse tissues. J. Histochem. Cytochem. 46, 449-457 (1998). (Pubitemid 28158464)
24. Milner R. Microglial expression of avb3 and avb5 integrins is regulated by cytokines and the extracellular matrix: b5 integrin null microglia show no defects in adhesion or MMP-9 expression on vitronectin. Glia 57, 714-723 (2009).
25. Proctor JM, Zang K, Wang D, Wang R, Reichardt LF. Vascular development of the brain requires b8 integrin expression in the neuroepithelium. J. Neurosci. 25, 9940-9948 (2005). (Pubitemid 41528032)
26. Zhu J, Motejlek K, Wang D, Zang K, Schmidt A, Reichardt LF. b8 integrins are required for vascular morphogenesis in mouse embryos. Development 129, 2891-2903 (2002). (Pubitemid 34874268)
27. Pardridge WM. Blood-brain barrier delivery. Drug Discov. Today 12, 54-61 (2007). (Pubitemid 46014479)
28. de Boer AG, van der Sandt IC, Gaillard PJ. The role of drug transporters at the blood-brain barrier. Annu. Rev. Pharmacol. Toxicol. 43, 629-656 (2003). (Pubitemid 37372656)
29. Begley DJ. Efflux Mechanisms in Central Nervous System: A Powerful Influence on Drug Distribution Within the Brain. Elsevier, (2004)
30. Loscher W, Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat. Rev. Neurosci. 6, 591-602 (2005). (Pubitemid 41059334)
31. Nagengast WB, Oude Munnink TH, Dijkers EC et al. Multidrug resistance in oncology and beyond: from imaging of drug efflux pumps to cellular drug targets. Methods Mol. Biol. 596, 15-31 (2010).
32. Ziegler G, Prinz V, Albrecht MW et al. Mrp-8 and -14 mediate CNS injury in focal cerebral ischemia. Biochim. Biophys. Acta 1792, 1198-1204 (2009).
33. Nicolazzo JA, Katneni K. Drug transport across the blood-brain barrier and the impact of breast cancer resistance protein (ABCG2). Curr. Top. Med. Chem. 9, 130-147 (2009).
34. Liu X, Chen C, Smith BJ. Progress in brain penetration evaluation in drug discovery and development. J. Pharmacol. Exp. Ther. 325, 349-356 (2008). (Pubitemid 351574780)
35. Katsura T, Inui K. Intestinal absorption of drugs mediated by drug transporters: mechanisms and regulation. Drug Metab. Pharmacokinet. 18, 1-15 (2003).
36. Dahlin A, Royall J, Hohmann JG, Wang J. Expression profiling of the solute carrier gene family in the mouse brain. J. Pharmacol. Exp. Ther. 329, 558-570 (2009).
37. Feng MR. Assessment of blood-brain barrier penetration: in silico, in vitro and in vivo. Curr. Drug Metab. 3, 647-657 (2002). (Pubitemid 35339328)
38. Alavijeh MS, Chishty M, Qaiser MZ, Palmer AM. Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery. NeuroRx 2, 554-571 (2005). (Pubitemid 41393265)
39. Cabrera MA, Bermejo M, Perez M, Ramos R. TOPS-MODE approach for the prediction of blood-brain barrier permeation. J. Pharm. Sci. 93, 1701-1717 (2004). (Pubitemid 38823699)
40. Liu X, Yeo H, Yau A, Van Natta K, Vilenski O, Weller P. Brain unbound drug concentration calculated from in vitro brain unbound fraction is consistent with brain extracellular fluid drug concentration measured by brain microdialysis for four model compounds. AAPS J. 9, 2439 (2007).
41. Liu X, Smith BJ, Chen C et al. Use of a physiologically based pharmacokinetic model to study the time to reach brain equilibrium: an experimental analysis of the role of blood-brain barrier permeability, plasma protein binding, and brain tissue binding. J. Pharmacol. Exp. Ther. 313, 1254-1262 (2005). (Pubitemid 40727030)
42. Pardridge WM. Log(BB), PS products and in silico models of drug brain penetration. Drug Discov. Today 9, 392-393 (2004). (Pubitemid 38479683)
43. Kalvass JC, Maurer TS, Pollack GM. Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: comparison of unbound concentration ratios to in vivo p-glycoprotein efflux ratios. Drug Metab. Dispos. 35, 660-666 (2007). (Pubitemid 46513270)
44. Gonzalez-Alvarez I, Fernandez-Teruel C, Garrigues TM, Casabo VG, Ruiz-Garcia A, Bermejo M. Kinetic modelling of passive transport and active efflux of a fluoroquinolone across Caco-2 cells using a compartmental approach in NONMEM. Xenobiotica 35, 1067-1088 (2005). (Pubitemid 43163247)
45. Mahar Doan KM, Wring SA, Shampine LJ et al. Steady-state brain concentrations of antihistamines in rats: interplay of membrane permeability, P-glycoprotein efflux and plasma protein binding. Pharmacology 72, 92-98 (2004). (Pubitemid 39179257)
46. Reichel A. Addressing central nervous system (CNS) penetration in drug discovery: basics and implications of the evolving new concept. Chem. Biodivers. 6, 2030-2049 (2009).
47. Jeffrey P, Summerfield S. Assessment of the blood-brain barrier in CNS drug discovery. Neurobiol. Dis. 37, 33-37 (2010).
48. Mensch J, Melis A, Mackie C et al. Evaluation of a combined high-throughput in vitro permeability assay with in silico P-gp estimations for the prediction of in vivo log BB data. Int. J. Pharma. 395(1-2), 182-197 (2010).
49. Clark D. Computational prediction of blood-brain barrier permeation. Annu. Rep. Med. Chem. 40, 403-415 (2005). (Pubitemid 43693171)
50. Engkvist O, Wrede P, Rester U. Prediction of CNS activity of compound libraries using substructure analysis. J. Chem. Inf. Comput. Sci. 43, 155-160 (2003).
51. Kerns EH, Di L. Drug-Like Properties: Concepts, Structure Design, And Methods: From Adme To Toxicity Optimization. Academic Press, Burlington, USA (2008).
52. Abraham MH. The factors that influence permeation across the blood-brain barrier. Eur. J. Med. Chem. 39, 235-240 (2004). (Pubitemid 38393750)
53. Norinder U, Haeberlein M. Computational approaches to the prediction of the blood-brain distribution. Adv. Drug. Deliv. Rev. 54, 291-313 (2002). (Pubitemid 34260955)
54. Abbott NJ. Prediction of blood-brain barrier permeation in drug discovery from in vivo, in vitro and in silico models. Drug Discov. Today. 1(4), 407-416 (2004). (Pubitemid 40186344)
55. Didziapetris R, Japertas P, Avdeef A, Petrauskas A. Classification analysis of P-glycoprotein substrate specificity. J. Drug Target. 11, 391-406 (2003). (Pubitemid 38455825)
56. Usansky HH, Sinko PJ. Computation of log BB values for compounds transported through carrier-mediated mechanisms using in vitro permeability data from brain microvessel endothelial cell (BMEC) monolayers. Pharm. Res. 20, 390-396 (2003). (Pubitemid 36288367)
57. Liu X, Tu M, Kelly RS, Chen C, Smith BJ. Development of a computational approach to predict blood-brain barrier permeability. Drug Metab. Dispos. 32, 132-139 (2004). (Pubitemid 38112545)
58. Young RC, Mitchell RC, Brown TH et al. Development of a new physicochemical model for brain penetration and its application to the design of centrally acting H2 receptor histamine antagonists. J. Med. Chem. 31, 656-671 (1988). (Pubitemid 18070588)
59. Calder JA, Ganellin CR. Predicting the brain-penetrating capability of histaminergic compounds. Drug Des. Discov. 11, 259-268 (1994). (Pubitemid 24216199)
60. Mensch J, Oyarzabal J, Mackie C, Augustijns P. In vivo, in vitro and in silico methods for small molecule transfer across the BBB. J. Pharm. Sci. 98, 4429-4468 (2009).
61. Clark DE. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood-brain barrier penetration. J. Pharm Sci. 88, 815-821 (1999). (Pubitemid 29398551)
62. Mehdipour AR, Hamidi M. Brain drug targeting: a computational approach for overcoming blood-brain barrier. Drug Discov. Today. 14, 1030-1036 (2009).
63. Abraham MH, Chadha HS, Mitchell RC. Hydrogen bonding. 33. Factors that influence the distribution of solutes between blood and brain. J. Pharm. Sci. 83, 1257-1268 (1994). (Pubitemid 24282331)
64. Norinder U. Refinement of catalyst hypotheses using simplex optimisation. J. Comput. Aided Mol. Des. 14, 545-557 (2000). (Pubitemid 30445058)
65. Bendels S, Kansy M, Wagner B, Huwyler J. In silico prediction of brain and CSF permeation of small molecules using PLS regression models. Eur. J. Med. Chem. 43, 1581-1592 (2008).
66. Winkler DA, Burden FR. Modelling blood- brain barrier partitioning using Bayesian neural nets. J. Mol. Graph. Model. 22, 499-505 (2004). (Pubitemid 38746575)
67. Hemmateenejad B, Miri R, Akhond M, Shamsipur M. Quantitative structure-activity relationship study of recently synthesized 1,4-dihydropyridine calcium channel antagonists. Application of the Hansch analysis method. Arch. Pharm. (Weinheim). 335, 472-480 (2002). (Pubitemid 36125515)
68. Zhang H. A new nonlinear equation for the tissue/blood partition coefficients of neutral compounds. J. Pharm. Sci. 93, 1595-1604 (2004). (Pubitemid 38725030)
69. Lundquist S, Renftel M. The use of in vitro cell culture models for mechanistic studies and as permeability screens for the blood-brain barrier in the pharmaceutical industry- background and current status in the drug discovery process. Vascul. Pharmacol. 38, 355-364 (2002). (Pubitemid 36398257)
70. Reichel A, Begley DJ, Abbott NJ. An overview of in vitro techniques for blood-brain barrier studies. Methods Mol. Med. 89, 307-324 (2003).
71. Pidgeon C, Ong S, Liu H et al. IAM chromatography: an in vitro screen for predicting drug membrane permeability. J. Med. Chem. 38, 590-594 (1995).
72. Stein W. Transport and Diffusion Across Cell Membranes. Academic Press, Orlando, FL, USA (1986).
73. Di L, Kerns EH, Fan K, McConnell OJ, Carter GT. High throughput artificial membrane permeability assay for blood-brain barrier. Eur. J. Med. Chem. 38, 223-232 (2003). (Pubitemid 36349665)
74. Carrara S, Reali V, Misiano P, Dondio G, Bigogno C. Evaluation of in vitro brain penetration: optimized PAMPA and MDCKII-MDR1 assay comparison. Int. J. Pharm. 345, 125-133 (2007). (Pubitemid 350103647)
75. Wexler DS, Gao L, Anderson F et al. Linking solubility and permeability assays for maximum throughput and reproducibility. J. Biomol. Screen. 10, 383-390 (2005). (Pubitemid 40800567)
76. Rodriguez-Franco MI, Fernandez- Bachiller MI, Perez C, Hernandez-Ledesma B, Bartolome B. Novel tacrine-melatonin hybrids as dual-acting drugs for Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties. J. Med. Chem. 49, 459-462 (2006). (Pubitemid 43157478)
77. Pavon FJ, Bilbao A, Hernandez-Folgado L et al. Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-3- hexyl-1H-1,2,4-triazole - LH 21. Neuropharmacology 51, 358-366 (2006). (Pubitemid 44081792)
78. Mensch J, Melis A, Mackie C, Verreck G, Brewster ME, Augustijns P. Evaluation of various PAMPA models to identify the most discriminating method for the prediction of BBB permeability. Eur. J. Pharm. Biopharm. 74(3), 495-502 (2010).
79. Kerns EH, Di L, Petusky S, Farris M, Ley R, Jupp P. Combined application of parallel artificial membrane permeability assay and Caco-2 permeability assays in drug discovery. J. Pharm. Sci. 93, 1440-1453 (2004). (Pubitemid 38725018)
80. Hartmann T, Schmitt J. Lipophilicity beyond octanol/water: a short comparison of modern technologies. Drug Discov. Today. 1, 431-439 (2004). (Pubitemid 40186347)
81. Comer JEA. High-Throughput Measurement of Log D and pKa. Wiley-VCH, Weinheim, Germany (2004).
82. de Boer AB, de Vries HE. Gaillard PJ, Breimer DD. Drug Transport Across the Blood-Brain Barrier: New Experimental Strategies. Harwood Scientific, Amsterdam (1997).
83. Pardridge WM. Holy grails and in vitro blood-brain barrier models. Drug Discov. Today. 9, 258 (2004). (Pubitemid 38328509)
84. Grant GA, Abbott NJ, Janigro D. Understanding the physiology of the blood-brain barrier: in vitro models. News Physiol. Sci. 13, 287-293 (1998).
85. Gaillard PJ, van der Sandt IC, Voorwinden LH et al. Astrocytes increase the functional expression of P-glycoprotein in an in vitro model of the blood-brain barrier. Pharm. Res. 17, 1198-1205 (2000).
86. Janzer RC, Raff MC. Astrocytes induce blood-brain barrier properties in endothelial cells. Nature 325, 253-257 (1987). (Pubitemid 17049884)
87. Meresse S, Dehouck MP, Delorme P et al. Bovine brain endothelial cells express tight junctions and monoamine oxidase activity in long-term culture. J. Neurochem. 53, 1363-1371 (1989). (Pubitemid 19267001)
88. Kim JA, Tran ND, Li Z, Yang F, Zhou W, Fisher MJ. Brain endothelial hemostasis regulation by pericytes. J. Cereb. Blood Flow Metab. 26, 209-217 (2006). (Pubitemid 43151577)
89. Butt AM, Jones HC, Abbott NJ. Electrical resistance across the blood-brain barrier in anaesthetized rats: a developmental study. J. Physiol. 429, 47-62 (1990). (Pubitemid 20327537)
90. Bickel U. How to measure drug transport across the blood-brain barrier. NeuroRx 2, 15-26 (2005). (Pubitemid 40128023)
91. Rist RJ, Romero IA, Chan MW, Couraud PO, Roux F, Abbott NJ. F-actin cytoskeleton and sucrose permeability of immortalised rat brain microvascular endothelial cell monolayers: effects of cyclic AMP and astrocytic factors. Brain Res. 768, 10-18 (1997). (Pubitemid 27433471)
92. Toimela T, Maenpaa H, Mannerstrom M, Tahti H. Development of an in vitro blood-brain barrier model-cytotoxicity of mercury and aluminum. Toxicol. Appl. Pharmacol. 195, 73-82 (2004). (Pubitemid 38177501)
93. Lauer R, Bauer R, Linz B et al. Development of an in vitro blood-brain barrier model based on immortalized porcine brain microvascular endothelial cells. Farmaco. 59, 133-137 (2004). (Pubitemid 38198270)
94. Nagasawa K, Ito S, Kakuda T et al. Transport mechanism for aluminum citrate at the blood-brain barrier: kinetic evidence implies involvement of system Xc- in immortalized rat brain endothelial cells. Toxicol. Lett. 155, 289-296 (2005). (Pubitemid 39643214)
95. Tetsuka K, Takanaga H, Ohtsuki S, Hosoya K, Terasaki T. The l-isomer-selective transport of aspartic acid is mediated by ASCT2 at the blood-brain barrier. J. Neurochem. 87, 891-901 (2003). (Pubitemid 37444565)
96. Rubin LL, Hall DE, Porter S et al. A cell culture model of the blood-brain barrier. J. Cell Biol. 115, 1725-1735 (1991). (Pubitemid 21910012)
97. Gaillard PJ, Voorwinden LH, Nielsen JL et al. Establishment and functional characterization of an in vitro model of the blood-brain barrier, comprising a co-culture of brain capillary endothelial cells and astrocytes. Eur. J. Pharm. Sci. 12, 215-222 (2001).
98. Tan KH, Dobbie MS, Felix RA, Barrand MA, Hurst RD. A comparison of the induction of immortalized endothelial cell impermeability by astrocytes. Neuroreport 12, 1329-1334 (2001). (Pubitemid 32476123)
99. Franke H, Galla HJ, Beuckmann CT. An improved low-permeability in vitro-model of the blood-brain barrier: transport studies on retinoids, sucrose, haloperidol, caffeine and mannitol. Brain Res. 818, 65-71 (1999). (Pubitemid 29227284)
100. Weksler BB, Subileau EA, Perriere N et al. Blood-brain barrier-specific properties of a human adult brain endothelial cell line. Faseb. J. 19, 1872-1874 (2005). (Pubitemid 41598779)
101. Neuhaus W, Lauer R, Oelzant S, Fringeli UP, Ecker GF, Noe CR. A novel flow based hollow-fiber blood-brain barrier in vitro model with immortalised cell line PBMEC/C1-2. J. Biotechnol. 125, 127-141 (2006). (Pubitemid 44066610)
102. Stanness KA, Guatteo E, Janigro D. A dynamic model of the blood-brain barrier 'in vitro'. Neurotoxicology 17, 481-496 (1996). (Pubitemid 26321348)
103. Stanness KA, Westrum LE, Fornaciari E et al. Morphological and functional characterization of an in vitro blood-brain barrier model. Brain Res. 771, 329-342 (1997). (Pubitemid 27492111)
104. Janigro D, Leaman SM, Stanness KA. Dynamic modeling of the blood-brain barrier: a novel tool for studies of drug delivery to the brain. Pharm. Sci. Technolo. Today 2, 7-12 (1999). (Pubitemid 29132899)
105. Dai H, Elmquist WF. Drug transport studies using quantitative microdialysis. Methods Mol. Med. 89, 249-264 (2003).
106. Polli JW, Baughman TM, Humphreys JE et al. P-glycoprotein influences the brain concentrations of cetirizine (Zyrtec), a second-generation nonsedating antihistamine. J. Pharm. Sci. 92, 2082-2089 (2003). (Pubitemid 37175638)
107. Wang Q, Rager JD, Weinstein K et al. Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier. Int. J. Pharm. 288, 349-359 (2005). (Pubitemid 40038588)
108. Gumbleton M, Audus KL. Progress and limitations in the use of in vitro cell cultures to serve as a permeability screen for the blood- brain barrier. J. Pharm. Sci. 90, 1681-1698 (2001). (Pubitemid 33062590)
109. Eisenblatter T, Galla HJ. A new multidrug resistance protein at the blood-brain barrier. Biochem. Biophys. Res. Commun. 293, 1273-1278 (2002). (Pubitemid 34681079)
110. Gao B, Stieger B, Noe B, Fritschy JM, Meier PJ. Localization of the organic anion transporting polypeptide 2 (Oatp2) in capillary endothelium and choroid plexus epithelium of rat brain. J. Histochem. Cytochem. 47, 1255-1264 (1999).
111. Doran A, Obach RS, Smith BJ et al. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab. Dispos. 33, 165-174 (2005). (Pubitemid 40023528)
112. Hirase T, Staddon JM, Saitou M et al. Occludin as a possible determinant of tight junction permeability in endothelial cells. J. Cell Sci. 110 (Pt 14), 1603-1613 (1997). (Pubitemid 27338748)
113. Hurst RD, Fritz IB. Properties of an immortalised vascular endothelial/glioma cell co-culture model of the blood-brain barrier. J. Cell Physiol. 167, 81-88 (1996). (Pubitemid 26108736)
114. Ramsohoye PV, Fritz IB. Preliminary characterization of glial-secreted factors responsible for the induction of high electrical resistances across endothelial monolayers in a blood-brain barrier model. Neurochem. Res. 23, 1545-1551 (1998). (Pubitemid 28516295)
115. Akiyama H, Kondoh T, Kokunai T, Nagashima T, Saito N, Tamaki N. Blood-brain barrier formation of grafted human umbilical vein endothelial cells in athymic mouse brain. Brain Res. 858, 172-176 (2000). (Pubitemid 30105796)
116. Memtrans Project EC. Alternative Testing Strategies - Progress Report 2009. Replacing, Reducing and Refining uUse of Animals in Research. Official Publications of the European Commission, Luxembourg (2009).
117. Centelles-Sanguesa A, Gunday N, Zengerly I et al. Prevalidation of in vitro models for prediction of secretion processes at intestinal level. Presented at: PharmSci Fair Exhibition. Nice, France, 8-12 June 2009.
118. Maurer TS, Debartolo DB, Tess DA, Scott DO. Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice. Drug Metab. Dispos. 33, 175-181 (2005). (Pubitemid 40023529)
119. Summerfield SG, Stevens AJ, Cutler L et al. Improving the in vitro prediction of in vivo central nervous system penetration: integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain. J. Pharmacol. Exp. Ther. 316, 1282-1290 (2006). (Pubitemid 43345304)
120. Becker S, Liu X. Evaluation of the utility of brain slice methods to study brain penetration. Drug Metab. Dispos. 34, 855-861 (2006).
121. Lazaro E, Rafols C, Abraham MH, Roses M. Chromatographic estimation of drug disposition properties by means of immobilized artificial membranes (IAM) and C18 columns. J. Med. Chem. 49, 4861-4870 (2006). (Pubitemid 44201044)
122. Salminen T, Pulli A, Taskinen J. Relationship between immobilised artificial membrane chromatographic retention and the brain penetration of structurally diverse drugs. J. Pharm. Biomed. Anal. 15, 469-477 (1997). (Pubitemid 26384301)
123. Pardridge WM. Isolated Brain Capillaries: An In Vitro Model of Blood-Brain Barrier Research. Cambridge University Press, Cambridge, UK, 49-61 (1998).
124. de Boer AG, Gaillard PJ. In vitro models of the blood-brain barrier: when to use which? Curr. Med. Chem. Central Nerv. Syst. Agents. 2, 203-209 (2002). (Pubitemid 36267725)
125. Cecchelli R, Dehouck B, Descamps L et al. In vitro model for evaluating drug transport across the blood-brain barrier. Adv. Drug Deliv. Rev. 36, 165-178 (1999). (Pubitemid 29121970)
126. Dehouck MP, Meresse S, Delorme P, Fruchart JC, Cecchelli R. An easier, reproducible, and mass-production method to study the blood-brain barrier in vitro. J. Neurochem. 54, 1798-1801 (1990).
127. Audus KL, Borchardt RT. Characterization of an in vitro blood-brain barrier model system for studying drug transport and metabolism. Pharm. Res. 3, 81-87 (1986). (Pubitemid 17191154)
128. Audus KL, Rose JM, Wang W, Borchardt RT. Brain Microvessel Endothelial Cell Culture System. Cambridge University Press, NY, USA 86-93 (1998).
129. Lundquist S, Renftel M, Brillault J, Fenart L, Cecchelli R, Dehouck MP. Prediction of drug transport through the blood-brain barrier in vivo: a comparison between two in vitro cell models. Pharm. Res. 19, 976-981 (2002). (Pubitemid 34804239)
130. Raub TJ, Kuentzel SL, Sawada GA. Permeability of bovine brain microvessel endothelial cells in vitro: barrier tightening by a factor released from astroglioma cells. Exp. Cell Res. 199, 330-340 (1992).
131. Glynn SL, Yazdanian M. In vitro blood-brain barrier permeability of nevirapine compared with other HIV antiretroviral agents. J. Pharm. Sci. 87, 306-310 (1998). (Pubitemid 28204583)
132. Rochat B, Baumann P, Audus KL. Transport mechanisms for the antidepressant citalopram in brain microvessel endothelium. Brain Res. 831, 229-236 (1999). (Pubitemid 29336205)
133. Bachmeier CJ, Spitzenberger TJ, Elmquist WF, Miller DW. Quantitative assessment of HIV-1 protease inhibitor interactions with drug efflux transporters in the blood-brain barrier. Pharm. Res. 22, 1259-1268 (2005). (Pubitemid 41176029)
134. Dingemanse J, Sollie FA, Breimer DD, Danhof M. Pharmacokinetic modeling of the anticonvulsant response of oxazepam in rats using the pentylenetetrazol threshold concentration as pharmacodynamic measure. J. Pharmacokinet. Biopharm. 16, 203-228 (1988).
135. Hilbert JM, Battista D. Quazepam and flurazepam: differential pharmacokinetic and pharmacodynamic characteristics. J. Clin. Psychiatry. 52 Suppl, 21-26 (1991).
136. Pardridge WM, Boado RJ, Farrell CR. Brain-type glucose transporter (GLUT-1) is selectively localized to the blood-brain barrier. Studies with quantitative western blotting and in situ hybridization. J. Biol Chem. 265, 18035-18040 (1990).
137. Hoheisel D, Nitz T, Franke H et al. Hydrocortisone reinforces the blood-brain properties in a serum free cell culture system. Biochem. Biophys. Res. Commun. 247, 312-315 (1998).
138. Kido Y, Tamai I, Nakanishi T et al. Evaluation of blood-brain barrier transporters by co-culture of brain capillary endothelial cells with astrocytes. Drug Metab. Pharmacokinet. 17, 34-41 (2002).
139. Reichel A, Begley DJ, Abbott NJ. Carrier-mediated delivery of metabotrophic glutamate receptor ligands to the central nervous system: structural tolerance and potential of the l-system amino acid transporter at the blood-brain barrier. J. Cereb. Blood Flow Metab. 20, 168-174 (2000). (Pubitemid 30019842)
140. Begley DJ, Lechardeur D, Chen ZD et al. Functional expression of P-glycoprotein in an immortalised cell line of rat brain endothelial cells, RBE4. J. Neurochem. 67, 988-995 (1996). (Pubitemid 26277910)
141. Lohmann C, Huwel S, Galla HJ. Predicting blood-brain barrier permeability of drugs: evaluation of different in vitro assays. J. Drug Target. 10, 263-276 (2002). (Pubitemid 34746308)
142. Polli JW, Humphreys JE, Wring SA et al. A comparison of Madin-Darby canine kidney cells and bovine brain endothelial cells as a blood-brain barrier screen in early drug discovery. In:Progress in the Reduction, Refinement and Replacement of Animal Experimentation. Balls M, van Zeller AM, Halder ME (Eds). Elsevier Sciences B.V., Amsterdam, The Netherlands, 271-289 (2000).
143. Hurst RD, Heales SJ, Dobbie MS, Barker JE, Clark JB. Decreased endothelial cell glutathione and increased sensitivity to oxidative stress in an in vitro blood-brain barrier model system. Brain Res. 802, 232-240 (1998). (Pubitemid 28392175)
144. Kuchler-Bopp S, Delaunoy JP, Artault JC, Zaepfel M, Dietrich JB. Astrocytes induce several blood-brain barrier properties in non-neural endothelial cells. Neuroreport. 10, 1347-1353 (1999). (Pubitemid 29403721)
145. Scism JL, Laska DA, Horn JW et al. Evaluation of an in vitro co-culture model for the blood-brain barrier: comparison of human umbilical vein endothelial cells (ECV304) and rat glioma cells (C6) from two commercial sources. In vitro Cell Dev. Biol. Anim. 35, 580-592 (1999). (Pubitemid 30007655)
146. Dagenais C, Rousselle C, Pollack GM, Scherrmann JM. Development of an in situ mouse brain perfusion model and its application to mdr1a P-glycoprotein-deficient mice. J. Cereb. Blood Flow Metab. 20, 381-386 (2000). (Pubitemid 30108457)
147. Pardridge WM. Transport of small molecules through the blood-brain barrier: biology and methodology. Adv. Drug Deliv. 15, 5-36 (1995).
148. Smith QR. A Review Of Blood-brain Barrier Transport Techniques. Human Press, 193-208 (2003).
149. Bonate PL. Animal models for studying transport across the blood-brain barrier. J. Neurosci. Methods. 56, 1-15 (1995).
150. Cisternino S, Mercier C, Bourasset F, Roux F, Scherrmann JM. Expression, up-regulation and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier. Cancer Res. 64, 3296-3301 (2004). (Pubitemid 38581436)
151. Schinkel AH. P-glycoprotein, a gatekeeper in the blood-brain barrier. Adv. Drug Deliv. Rev. 36, 179-194 (1999). (Pubitemid 29121971)
152. Sisodiya SM, Martinian L, Scheffer GL et al. Major vault protein, a marker of drug resistance, is upregulated in refractory epilepsy. Epilepsia 44, 1388-1396 (2003). (Pubitemid 37385846)
153. Martin I. Prediction of blood-brain barrier penetration: are we missing the point? Drug Discov. Today. 9, 161-162 (2004). (Pubitemid 38199960)
154. Jeffrey P, Summerfield SG. Challenges for blood-brain barrier (BBB) screening. Xenobiotica 37, 1135-1151 (2007). (Pubitemid 350041554)
155. Bostrom E, Simonsson US, Hammarlund- Udenaes M. In vivo blood-brain barrier transport of oxycodone in the rat: indications for active influx and implications for pharmacokinetics/pharmacodynamics. Drug Metab. Dispos. 34, 1624-1631 (2006). (Pubitemid 44285405)
156. Gupta A, Chatelain P, Massingham R, Jonsson EN, Hammarlund-Udenaes M. Brain distribution of cetirizine enantiomers: comparison of three different tissue-to-plasma partition coefficients: K(p), K(p,u), and K(p,uu). Drug Metab. Dispos. 34, 318-323 (2006). (Pubitemid 43145034)
157. Banks WA, Kastin AJ, Ehrensing CA. Endogenous peptide Tyr-Pro-Trp-Gly-NH2 (Tyr-W-MIF-1) is transported from the brain to the blood by peptide transport system-1. J. Neurosci. Res. 35, 690-695 (1993). (Pubitemid 23226720)
158. Raub TJ. Strategies for optimizing blood-brain barrier penetration. Presented at: Workshop On Optimization Of Drug-Like Properties During Lead Optimization. Parsippany, NJ, USA, (2004).
159. Kusuhara H, Sekine T, Utsunomiya- Tate N et al. Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J. Biol. Chem. 274, 13675-13680 (1999).
160. Kitazawa T, Terasaki T, Suzuki H, Kakee A, Sugiyama Y. Efflux of taurocholic acid across the blood-brain barrier: interaction with cyclic peptides. J. Pharmacol. Exp. Ther. 286, 890-895 (1998). (Pubitemid 29003482)
161. de Lange EC, Danhof M, de Boer AG, Breimer DD. Methodological considerations of intracerebral microdialysis in pharmacokinetic studies on drug transport across the blood- brain barrier. Brain Res. Brain Res. Rev. 25, 27-49 (1997). (Pubitemid 27459719)
162. Sawchuk RJ, Elmquist WF. Microdialysis in the study of drug transporters in the CNS. Adv. Drug Deliv. Rev. 45, 295-307 (2000).
163. Chen YF, Chang CH, Wang SC, Tsai TH. Measurement of unbound cocaine in blood, brain and bile of anesthetized rats using microdialysis coupled with liquid chromatography and verified by tandem mass spectrometry. Biomed. Chromatogr. 19, 402-408 (2005).
164. Qiao JP, Abliz Z, Chu FM et al. Microdialysis combined with liquid chromatography-tandem mass spectrometry for the determination of 6-aminobutylphthalide and its main metabolite in the brains of awake freely-moving rats. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 805, 93-99 (2004). (Pubitemid 38534407)
165. Chaurasia CS, Muller M, Bashaw ED et al. AAPS-FDA workshop white paper: microdialysis principles, application and regulatory perspectives. Pharm. Res. 24, 1014-1025 (2007). (Pubitemid 46675390)
166. de Lange EC, Ravenstijn PG, Groenendaal D, van Steeg TJ. Toward the prediction of CNS drug-effect profiles in physiological and pathological conditions using microdialysis and mechanism-based pharmacokinetic- pharmacodynamic modeling. AAPS J. 7, E532-543 (2005).
167. Fenstermacher DA, Joseph DR. Analysis of promoter and androgen regulatory sequences required for optimal transcription of the rat androgen-binding protein gene. J. Androl. 19, 81-91 (1998). (Pubitemid 28090863)
168. Wei L, Craven K, Erinjeri J et al. Local cerebral blood flow during the first hour following acute ligation of multiple arterioles in rat whisker barrel cortex. Neurobiol. Dis. 5, 142-150 (1998). (Pubitemid 28520949)
169. Hazai I, Patfalusi M, Klebovich I, Urmos I. Whole-body autoradiography and quantitative organ-level distribution study of deramciclane in rats. J. Pharm. Pharmacol. 51, 165-174 (1999). (Pubitemid 29131309)
170. Coloma MJ, Lee HJ, Kurihara A et al. Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor. Pharm. Res. 17, 266-274 (2000) (Pubitemid 30225129)
171. Plenevaux A, Weissmann D, Aerts J et al. Tissue distribution, autoradiography, and metabolism of 4-(2'-methoxyphenyl)-1-[2' -[N-2'-pyridinyl)-p-[(18)F] fluorobenzamido]ethyl]piperazine (p-[(18) F]MPPF), a new serotonin 5-HT(1A) antagonist for positron emission tomography: an in vivo study in rats. J. Neurochem. 75, 803-811 (2000).
172. Polli JW, Jarrett JL, Studenberg SD et al. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharm. Res. 16, 1206-1212 (1999). (Pubitemid 29393608)
173. Jiang Q, Ewing JR, Ding GL et al. Quantitative evaluation of BBB permeability after embolic stroke in rat using MRI. J. Cereb. Blood Flow Metab. 25, 583-592 (2005). (Pubitemid 40562931)
174. Wuerfel J, Bellmann-Strobl J, Brunecker P et al. Changes in cerebral perfusion precede plaque formation in multiple sclerosis: a longitudinal perfusion MRI study. Brain 127, 111-119 (2004). (Pubitemid 38055350)
175. Floris S, Blezer EL, Schreibelt G et al. Blood-brain barrier permeability and monocyte infiltration in experimental allergic encephalomyelitis: a quantitative MRI study. Brain 127, 616-627 (2004). (Pubitemid 38295477)
176. Perkins AC, Frier M. Radionuclide imaging in drug development. Curr. Pharm. Des. 10, 2907-2921 (2004). (Pubitemid 39220312)
177. Pike VW. PET radiotracers: crossing the blood-brain barrier and surviving metabolism. Trends Pharmacol. Sci. 30, 431-440 (2009).
178. Luurtsema G, de Lange EC, Lammertsma AA, Franssen EJ. Transport across the blood-brain barrier: stereoselectivity and PET-tracers. Mol. Imaging Biol. 6, 306-318 (2004). (Pubitemid 39243064)
179. Luurtsema G, Molthoff CF, Schuit RC, Windhorst AD, Lammertsma AA, Franssen EJ. Evaluation of (R)-[11C] verapamil as PET tracer of P-glycoprotein function in the blood-brain barrier: kinetics and metabolism in the rat. Nucl. Med. Biol. 32, 87-93 (2005). (Pubitemid 40187385)
180. Bart J, Dijkers EC, Wegman TD et al. New positron emission tomography tracer [(11)C]carvedilol reveals P-glycoprotein modulation kinetics. Br. J. Pharmacol. 145, 1045-1051 (2005). (Pubitemid 43079976)
181. Sasongko L, Link JM, Muzi M et al. Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clin. Pharmacol. Ther. 77, 503-514 (2005). (Pubitemid 40824964)
182. Gabathuler R. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol. Dis. 37, 48-57 (2010).
183. Alam MI, Beg S, Samad A et al. Strategy for effective brain drug delivery. Eur. J. Pharm. Sci. 40(5), 385-403 (2010).
184. Nagaraja TN, Patel P, Gorski M, Gorevic PD, Patlak CS, Fenstermacher JD. In normal rat, intraventricularly administered insulin-like growth factor-1 is rapidly cleared from CSF with limited distribution into brain. Cerebrospinal Fluid Res. 2, 5 (2005).
185. Patel NK, Bunnage M, Plaha P, Svendsen CN, Heywood P, Gill SS. Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. Ann. Neurol. 57, 298-302 (2005). (Pubitemid 40179870)
186. Slevin JT, Gerhardt GA, Smith CD, Gash DM, Kryscio R, Young B. Improvement of bilateral motor functions in patients with Parkinson's disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J. Neurosurg. 102, 216-222 (2005). (Pubitemid 43194069)
187. Mardor Y, Rahav O, Zauberman Y et al. Convection-enhanced drug delivery: increased efficacy and magnetic resonance image monitoring. Cancer Res. 65, 6858-6863 (2005). (Pubitemid 41065083)
188. Ohata K, Marmarou A. Clearance of brain edema and macromolecules through the cortical extracellular space. J. Neurosurg. 77, 387-396 (1992).
189. Wells DJ. Opening the floodgates: clinically applicable hydrodynamic delivery of plasmid DNA to skeletal muscle. Mol. Ther. 10, 207-208 (2004). (Pubitemid 39127367)
190. Wolff JA, Budker V. The mechanism of naked DNA uptake and expression. Adv. Genet. 54, 3-20 (2005).
191. Krewson CE, Klarman ML, Saltzman WM. Distribution of nerve growth factor following direct delivery to brain interstitium. Brain Res. 680, 196-206 (1995).
192. Daly TM. Overview of adeno-associated viral vectors. Methods Mol. Biol. 246, 157-165 (2004).
193. Burger C, Nash K, Mandel RJ. Recombinant adeno-associated viral vectors in the nervous system. Hum. Gene Ther. 16, 781-791 (2005). (Pubitemid 40982327)
194. Gao G, Alvira MR, Somanathan S et al. Adeno-associated viruses undergo substantial evolution in primates during natural infections. Proc. Natl Acad. Sci. USA 100, 6081-6086 (2003). (Pubitemid 36576934)
195. Grimm D, Kay MA. From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy. Curr. Gene Ther. 3, 281-304 (2003).
196. Tsuji D, Kuroki A, Ishibashi Y, Itakura T, Itoh K. Metabolic correction in microglia derived from Sandhoff disease model mice. J. Neurochem. 94, 1631-1638 (2005). (Pubitemid 41324644)
197. Kobayashi H, Carbonaro D, Pepper K et al. Neonatal gene therapy of MPS I mice by intravenous injection of a lentiviral vector. Mol. Ther. 11, 776-789 (2005). (Pubitemid 40567982)
198. Fjord-Larsen L, Johansen JL, Kusk P et al. Efficient in vivo protection of nigral dopaminergic neurons by lentiviral gene transfer of a modified Neurturin construct. Exp. Neurol. 195, 49-60 (2005). (Pubitemid 41116813)
199. Georgievska B, Jakobsson J, Persson E, Ericson C, Kirik D, Lundberg C. Regulated delivery of glial cell line-derived neurotrophic factor into rat striatum, using a tetracycline-dependent lentiviral vector. Hum. Gene Ther. 15, 934-944 (2004). (Pubitemid 39372570)
200. Vezzani A. Gene therapy in epilepsy. Epilepsy Curr. 4, 87-90 (2004).
201. Crozet C, Lin YL, Mettling C et al. Inhibition of PrPSc formation by lentiviral gene transfer of PrP containing dominant negative mutations. J. Cell Sci. 117, 5591-5597 (2004). (Pubitemid 40012205)
202. Steffens S, Tebbets J, Kramm CM, Lindemann D, Flake A, Sena-Esteves M. Transduction of human glial and neuronal tumor cells with different lentivirus vector pseudotypes. J. Neurooncol. 70, 281-288 (2004). (Pubitemid 40057956)
203. Wong LF, Ralph GS, Walmsley LE et al. Lentiviral-mediated delivery of Bcl-2 or GDNF protects against excitotoxicity in the rat hippocampus. Mol. Ther. 11, 89-95 (2005). (Pubitemid 40012002)
204. Kumar P, Wu H, McBride JL et al. Transvascular delivery of small interfering RNA to the central nervous system. Nature. 448, 39-43 (2007). (Pubitemid 47037001)
205. Miller G. Drug targeting. Breaking down barriers. Science 297, 1116-1118 (2002). (Pubitemid 36193322)
206. Erdlenbruch B, Alipour M, Fricker G et al. Alkylglycerol opening of the blood-brain barrier to small and large fluorescence markers in normal and C6 glioma-bearing rats and isolated rat brain capillaries. Br. J. Pharmacol. 140, 1201-1210 (2003). (Pubitemid 38117424)
207. Prados MD, Schold SJS, Fine HA et al. A randomized, double-blind, placebo-controlled, Phase II study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma. Neuro. Oncol. 5, 96-103 (2003). (Pubitemid 36416838)
208. Dietz GP, Bahr M. Delivery of bioactive molecules into the cell: the Trojan horse approach. Mol. Cell Neurosci. 27, 85-131 (2004). (Pubitemid 39370094)
209. Oldendorf WH, Szabo J. Amino acid assignment to one of three blood-brain barrier amino acid carriers. Am. J. Physiol. 230, 94-98 (1976).
210. Oldendorf WH. Brain uptake of radiolabeled amino acids, amines, and hexoses after arterial injection. Am. J. Physiol. 221, 1629-1639 (1971).
211. Krause M, Stark H, Schunack W. Azomethine prodrugs of (R)-a-methylhistamine, a highly potent and selective histamine H3-receptor agonist. Curr. Med. Chem. 8, 1329-1340 (2001). (Pubitemid 32791799)
212. Deguchi Y, Hayashi H, Fujii S et al. Improved brain delivery of a nonsteroidal anti-inflammatory drug with a synthetic glyceride ester: a preliminary attempt at a CNS drug delivery system for the therapy of Alzheimer's disease. J. Drug Target. 8, 371-381 (2000). (Pubitemid 32366705)
213. Frey HH, Popp C, Loscher W. Influence of inhibitors of the high affinity GABA uptake on seizure thresholds in mice. Neuropharmacology. 18, 581-590 (1979). (Pubitemid 9206168)
214. el Kihel L, Bourass J, Richomme P, Petit JY, Letourneux Y. Synthesis and evaluation of the anti-inflammatory effects of niflumic acid lipophilic prodrugs in brain edema. Arzneimittelforschung. 46, 1040-1044 (1996).
215. Hersh LB, Aboukhair N, Watson S. Immunohistochemical localization of aminopeptidase M in rat brain and periphery: relationship of enzyme localization and enkephalin metabolism. Peptides 8, 523-532 (1987). (Pubitemid 17119188)
216. Danks MK, Yoon KJ, Bush RA et al. Tumor-targeted enzyme/prodrug therapy mediates long-term disease-free survival of mice bearing disseminated neuroblastoma. Cancer Res. 67, 22-25 (2007). (Pubitemid 46142755)
217. Singhal D, Morgan ME, Anderson BD. Role of brain tissue localized purine metabolizing enzymes in the central nervous system delivery of anti-HIV agents 2′-b-fluoro-2′,3′-dideoxyinosine and 2′-b-fluoro- 2′,3′-dideoxyadenosine in rats. Pharm. Res. 14, 786-792 (1997). (Pubitemid 27281675)
218. Perioli L, Ambrogi V, Bernardini C et al. Potential prodrugs of nonsteroidal anti-inflammatory agents for targeted drug delivery to the CNS. Eur. J. Med. Chem. 39, 715-727 (2004). (Pubitemid 38970086)
219. Pardridge WM. Drug targeting to the brain. Pharm. Res. 24, 1733-1744 (2007). (Pubitemid 47206623)
220. Tamai I, Tsuji A. Transporter-mediated permeation of drugs across the blood-brain barrier. J. Pharm. Sci. 89, 1371-1388 (2000).
221. Killian DM, Hermeling S, Chikhale PJ. Targeting the cerebrovascular large neutral amino acid transporter (LAT1) isoform using a novel disulfide-based brain drug delivery system. Drug Deliv. 14, 25-31 (2007). (Pubitemid 44764456)
222. Bonina FP, Arenare L, Palagiano F et al. Synthesis, stability, and pharmacological evaluation of nipecotic acid prodrugs. J. Pharm. Sci. 88, 561-567 (1999). (Pubitemid 29220985)
223. Bilsky EJ, Egleton RD, Mitchell SA et al. Enkephalin glycopeptide analogues produce analgesia with reduced dependence liability. J. Med. Chem. 43, 2586-2590 (2000). (Pubitemid 30437141)
224. Battaglia G, La Russa M, Bruno V et al. Systemically administered d-glucose conjugates of 7-chlorokynurenic acid are centrally available and exert anticonvulsant activity in rodents. Brain Res. 860, 149-156 (2000). (Pubitemid 30155848)
225. Bonina FP, Arenare L, Ippolito R et al. Synthesis, pharmacokinetics and anticonvulsant activity of 7-chlorokynurenic acid prodrugs. Int. J. Pharm. 202, 79-88 (2000). (Pubitemid 30466232)
226. Bonina F, Puglia C, Rimoli MG et al. Glycosyl derivatives of dopamine and l-dopa as anti-Parkinson prodrugs: synthesis, pharmacological activity and in vitro stability studies. J. Drug Target. 11, 25-36 (2003). (Pubitemid 36527393)
227. Yang C, Tirucherai GS, Mitra AK. Prodrug based optimal drug delivery via membrane transporter/receptor. Expert Opin. Biol. Ther. 1, 159-175 (2001). (Pubitemid 33770074)
228. Boado RJ, Hui EK, Lu JZ, Pardridge WM. Drug targeting of erythropoietin across the primate blood-brain barrier with an IgG molecular Trojan horse. J. Pharmacol Exp. Ther. 333, 961-969
229. Boado RJ, Pardridge WM. Comparison of blood-brain barrier transport of glial-derived neurotrophic factor (GDNF) and an IgG-GDNF fusion protein in the rhesus monkey. Drug Metab. Dispos. 37, 2299-2304 (2009).
230. Pardridge WM. Preparation of Trojan horse liposomes (THLs) for gene transfer across the blood-brain barrier. Cold Spring Harb. Protoc. DOI:10.1101/pdb.prot5407 (2010).
231. Pardridge WM. Biopharmaceutical drug targeting to the brain. J. Drug Target. 18, 157-167 (2010).
232. Pinnen F, Cacciatore I, Cornacchia C et al. Codrugs linking l-dopa and sulfur-containing antioxidants: new pharmacological tools against Parkinson's disease. J. Med. Chem. 52, 559-563 (2009).
233. Sozio P, D'Aurizio E, Iannitelli A et al. Ibuprofen and lipoic acid diamides as potential codrugs with neuroprotective activity. Arch. Pharm. (Weinheim) 343, 133-142 (2010).
234. Rigor RR, Hawkins BT, Miller DS. Activation of PKC isoform b(I) at the blood- brain barrier rapidly decreases P-glycoprotein activity and enhances drug delivery to the brain. J. Cereb. Blood Flow Metab. 30(7), 1373-83 (2010).
235. Hanson LR, Frey WH 2nd. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci. 9 (Suppl. 3), S5 (2008).
236. Vyas TK, Shahiwala A, Marathe S, Misra A. Intranasal drug delivery for brain targeting. Curr. Drug Deliv. 2, 165-175 (2005). (Pubitemid 40488626)
237. Frey WH 2nd. Bypassing the blood-brain barrier to delivery therapeutics agents to the brain and spinal cord. Drug Delivery Technology. 5, 46-49 (2002).
238. Illum L. Is nose-to-brain transport of drugs in man a reality? J. Pharm. Pharmacol. 56, 3-17 (2004). (Pubitemid 38195323)
239. Costantino HR, Illum L, Brandt G, Johnson PH, Quay SC. Intranasal delivery: physicochemical and therapeutic aspects. Int. J. Pharm. 337, 1-24 (2007). (Pubitemid 46756063)
240. De Rosa R, Garcia AA, Braschi C et al. Intranasal administration of nerve growth factor (NGF) rescues recognition memory deficits in AD11 anti-NGF transgenic mice. Proc. Natl Acad. Sci. USA 102, 3811-3816 (2005). (Pubitemid 40360709)
241. Capsoni S, Giannotta S, Cattaneo A. Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in antinerve growth factor mice. Proc. Natl Acad. Sci. USA 99, 12432-12437 (2002).
242. Matsuoka Y, Gray AJ, Hirata-Fukae C et al. Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage. J. Mol. Neurosci. 31, 165-170 (2007). (Pubitemid 46742300)
243. Matsuoka Y, Jouroukhin Y, Gray AJ et al. A neuronal microtubule- interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. J. Pharmacol. Exp. Ther. 325, 146-153 (2008). (Pubitemid 351439178)
244. Visochek L, Steingart RA, Vulih-Shultzman I et al. PolyADP-ribosylation is involved in neurotrophic activity. J. Neurosci. 25, 7420-7428 (2005). (Pubitemid 41129815)
245. Steen E, Terry BM, Rivera EJ et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease - is this type 3 diabetes? J. Alzheimers Dis. 7, 63-80 (2005). (Pubitemid 40387185)
246. Liu XF, Fawcett JR, Hanson LR, Frey WH 2nd. The window of opportunity for treatment of focal cerebral ischemic damage with noninvasive intranasal insulin-like growth factor-I in rats. J. Stroke Cerebrovasc. Dis. 13, 16-23 (2004). (Pubitemid 38419175)
247. Reger MA, Watson GS, Green PS et al. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-b in memory-impaired older adults. J. Alzheimers Dis. 13, 323-331 (2008). (Pubitemid 352039034)
248. Reger MA, Watson GS, Green PS et al. Intranasal insulin improves cognition and modulates b-amyloid in early AD. Neurology 70, 440-448 (2008).
249. Jin K, Xie L, Childs J et al. Cerebral neurogenesis is induced by intranasal administration of growth factors. Ann. Neurol. 53, 405-409 (2003). (Pubitemid 36258647)
250. Wissing SA, Kayser O, Muller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv. Drug Deliv. Rev. 56, 1257-1272 (2004). (Pubitemid 38510473)
251. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J. Control. Release. 70, 1-20 (2001). (Pubitemid 32144788)
252. Ross TM, Martinez PM, Renner JC, Thorne RG, Hanson LR, Frey WH 2nd. Intranasal administration of interferon-b bypasses the blood-brain barrier to target the central nervous system and cervical lymph nodes: a noninvasive treatment strategy for multiple sclerosis. J. Neuroimmunol. 151, 66-77 (2004). (Pubitemid 38624401)
253. Alyautdin RN, Gothier D, Petrov V, Kharkevich D, Kreuter J. Analgesic activity of the hexapeptide dalargin absorbed on the surface of polysrbate 80-coated poly(butyl cyanoacrylate) nanoparticles. Eur. J.Pharm. Biopharm. 41, 44-48 (1995).
254. Kreuter J, Alyautdin RN, Kharkevich DA, Ivanov AA. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res. 674, 171-174 (1995).
255. Steiniger SC, Kreuter J, Khalansky AS et al. Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int. J. Cancer 109, 759-767 (2004). (Pubitemid 38405625)
256. Thorne RG, Pronk GJ, Padmanabhan V, Frey WH 2nd. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 127, 481-496 (2004). (Pubitemid 38950662)
257. Yu YP, Xu QQ, Zhang Q, Zhang WP, Zhang LH, Wei EQ. Intranasal recombinant human erythropoietin protects rats against focal cerebral ischemia. Neurosci. Lett. 387, 5-10 (2005). (Pubitemid 41138199)
258. Wang D, Gao Y, Yun L. Study on brain targeting of raltitrexed following intranasal administration in rats. Cancer Chemother. Pharmacol. 57, 97-104 (2006). (Pubitemid 41704922)
259. Barakat NS, Omar SA, Ahmed AA. Carbamazepine uptake into rat brain following intra-olfactory transport. J. Pharm. Pharmacol. 58, 63-72 (2006). (Pubitemid 43041997)
260. Olivier JC. Drug transport to brain with targeted nanoparticles. NeuroRx 2, 108-119 (2005).
261. Onishi H, Machida Y, Machida Y. Antitumor properties of irinotecan-containing nanoparticles prepared using poly(d,l-lactic acid) and poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol). Biol. Pharm. Bull. 26, 116-119 (2003). (Pubitemid 39663658)
262. Feng SS, Mu L, Win KY, Huang G. Nanoparticles of biodegradable polymers for clinical administration of paclitaxel. Curr. Med. Chem. 11, 413-424 (2004). (Pubitemid 38294346)
263. Fishbein I, Chorny M, Rabinovich L, Banai S, Gati I, Golomb G. Nanoparticulate delivery system of a tyrphostin for the treatment of restenosis. J. Control. Release. 65, 221-229 (2000). (Pubitemid 30122927)
264. Elamanchili P, Diwan M, Cao M, Samuel J. Characterization of poly(d,l-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells. Vaccine 22, 2406-2412 (2004). (Pubitemid 38757337)
265. Pangalos MN, Schechter LE, Hurko O. Drug development for CNS disorders: strategies for balancing risk and reducing attrition. Nat. Rev. Drug Discov. 6, 521-532 (2007). (Pubitemid 47019441)
266. Brookhaven National Laboratory, Chemistry Department. Awake animal PET imaging with the ratCAP (rat conscious animal PET). www.chemistry.bnl.gov/ ratcap/index.html
267. International Brain Barriers Society. www.ibbsoc.org